SecBot SecBot
SECBOTREPLAY Home › Report › TCRX

TCRX · TScan Therapeutics reported positive initial data from Cohort C of the…

TScan Therapeutics, Inc. · 8-K filed Jun 22, 2026 at 07:09 ET

At the news

BULLISHIMPACT 6/10

8-K filed Jun 22, 2026 at 07:09 ET

TScan Therapeutics reported positive initial data from Cohort C of the ALLOHA Phase 1 study for TSC-101, showing 11 of 14 patients achieved complete donor chimerism within ~3 weeks of first infusion, with a 93% response rate and a ~90% manufacturing success rate using the commercial-ready process. The company remains on track to enroll the first patient in the pivotal Phase 3 ALLOHA-2 study this month, de-risking the program and supporting advancement toward a registrational trial.

  • 11 of 14 patients achieved complete donor chimerism within ~3 weeks of first TSC-101 infusion
  • 93% of patients (13/14) responded with decreasing recipient chimerism
  • ~90% manufacturing success rate (17/19) with commercial-ready process
  • Safety profile consistent with Cohort A; no new safety signals

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access